The Psychedelic Executive Order Will Send Thousands to Mexico. Here’s How to Tell a Real 5-MeO-DMT Retreat From a Hashtag
You probably saw the news. The Executive Order. Psychedelics finally going mainstream. And maybe, quietly, you’ve been wondering if this is your moment.
We’ve been thinking about that too.
Here’s the honest version. The EO is real. The funding is real. But it won’t put 5-MeO-DMT within reach in the US next month, or next year. What it will do, almost immediately, is send a lot of people looking. Most will start by Googling “psychedelic retreat Mexico” without much idea what to look for.
That’s why we wrote this. Not as another news summary. You can find those everywhere. This is the kind of read we’d want a friend to have before they booked anything. A guide for telling the difference between a real retreat and a hashtag.
What the EO does (and doesn’t do)
.jpg)
So what did the President actually sign?
The short version: the Executive Order, signed April 18, 2026, fast-tracks FDA review of psychedelic compounds with Breakthrough Therapy status. It puts $50 million of federal funding behind ibogaine research through ARPA-H. It expands Right to Try access for people with serious mental illness, and tells the VA to lean further into clinical trials with veterans.
What it doesn’t do matters just as much. It doesn’t legalize anything. It doesn’t reschedule any compound. And it doesn’t mention 5-MeO-DMT by name. The EO is mostly an ibogaine and psilocybin story, driven by veteran advocacy.
But laws aren’t the only thing news moves. Attention is. Search interest in “psychedelic retreat” spikes after a story like this. Most of that interest lands in Mexico, where 5-MeO-DMT work already happens legally. Which is fine, if you know what you’re booking.
How the EO got onto the President’s desk
Worth understanding how the news got here. It tells you something about who’s been doing the actual work.
The catalyst was veterans. In 2024 and 2025, Stanford researchers tracked thirty Special Operations veterans with traumatic brain injury and PTSD who flew to Mexico for a single ibogaine session. A month later, PTSD symptoms were down 88%. A year later, 71% no longer met diagnostic criteria.
Then came the testimony. Former Navy SEAL Robert O’Neill, Green Beret Chris Thompson, and Medal of Honor recipient Dakota Meyer spoke at the Texas Capitol in April 2025 in support of state-funded ibogaine research. Texas signed Senate Bill 2308, a $50 million ibogaine clinical trial program, into law that summer.
At the federal level, HHS Secretary Robert F. Kennedy Jr. made psychedelic access a stated priority. And the catalysing moment, by Trump’s own account: a text from Joe Rogan about ibogaine, with the reply “Sounds great. Do you want FDA approval? Let’s do it.”
So the policy story is, almost entirely, a veterans-and-ibogaine story. Our partners at Bassé Ibogaine, and researchers like Dr. Deborha Mash, have spent years on this work. We’re not claiming a piece of it. But the door it’s opening is wider than ibogaine alone.
Why 5-MeO-DMT is a different vetting problem
If you’ve spent time researching plant medicines, here’s the trap: the lessons don’t fully transfer.
The first reason is pharmacology. The peak of a 5-MeO-DMT experience is roughly 20 minutes. There’s no slow ascent.
The intensity arrives in under a minute. Whoever’s holding the space either has the skill for that moment, or they don’t. There’s no margin to figure it out as it unfolds.
The second is lineage, and it’s the part most marketing gets wrong. 5-MeO-DMT was first synthesised in 1936. The Sonoran Desert toad story you may have read often conflates 5-MeO-DMT with bufotenine, a different compound.
There’s no documented tradition of intentional 5-MeO-DMT use in indigenous practice. So when a retreat sells “ancient shamanic 5-MeO-DMT,” the lineage isn’t real. The compound is post-1936, and its modern use is post-1990s.
The third is trauma. 5-MeO-DMT can surface PTSD material at the peak of the experience. The skill the moment demands is psychological: recognizing dissociation, knowing when to ground, knowing when to do nothing.
This isn’t a knock on plant-medicine traditions. It’s just a different job, asking for different training.
Plant-medicine practitioners and trauma-trained 5-MeO-DMT facilitators: what’s actually different
A shaman working with ayahuasca, peyote, or iboga is doing something legitimate. These traditions stretch back centuries.
The training is real, the lineage is real, and the framework (spirit, ceremony, healer relationship) is honoured by the people inside it.
5-MeO-DMT facilitation is a different thing entirely. Not lesser. Different.
The frame is different. A shaman moves inside a cosmology. A trauma-trained 5-MeO-DMT facilitator moves inside a model of nervous-system regulation, attachment, and somatic awareness.
Both frames are useful. Only one of them is the right map for what happens at the peak of a 20-minute 5-MeO-DMT session.
The screening is different. Plant-medicine intake is often informal, weighted toward intention and readiness. A 5-MeO-DMT intake, the version we run anyway, looks at psychiatric history, current medication (especially MAOIs and SSRIs), and cardiovascular markers.
The in-session response is different. If a guest enters dissociation, the response isn’t ceremonial. It’s stabilisation, titration, and co-regulation. The language of trauma work, not the language of spirit work.
The training pathway is different. The public benchmark for 5-MeO-DMT facilitator training is F.I.V.E.’s 9-month trauma-informed refinement program, which our co-founder Victoria Wueschner runs.
Apprenticeship inside a shamanic tradition is a real credential. For plant medicine. It doesn’t transfer here automatically, the same way trauma-trained facilitator credentials don’t transfer the other way.
Different lineages. Different toolkits. Same goal: someone arriving home in their body.
How to vet any 5-MeO-DMT retreat (including ours)
If you take one thing from this post, take this list. Use it on us. Use it on anyone.
1. Is the 5-MeO-DMT synthetic, and can they tell you why that matters?
Synthetic gives a known dose. Toad-derived contains bufotenine and other variable compounds, including ones that affect the heart.
We use synthetic exclusively. If a retreat won’t tell you which, that’s the answer.
2. Is there licensed medical staff on-site during ceremonies?
This isn’t optional with 5-MeO-DMT. Cardiovascular response can be intense, and we have a physician on-site for every ceremony.
If a retreat doesn’t name medical staff on its site, ask. If they can’t answer, walk.
3. What’s the intake screening?
Specifically: psychiatric history, current medications (MAOIs and SSRIs especially), and cardiovascular markers. If there’s no screening call before you put down a deposit, the answer is that there’s no screening.
4. What’s the facilitator’s training pathway?
A real answer names a programme. F.I.V.E.’s trauma-informed refinement training is the public benchmark for 5-MeO-DMT specifically. “I’ve done this hundreds of times” isn’t a training pathway.
5. What does the work after the ceremony look like, and for how long?
The ceremony is the start, not the deliverable. We run two weeks of preparation before and four weeks of integration support after. A retreat that ends when you fly home is a retreat that ends too early.
6. How many guests at a time?
Our cap is six. Above that, one-to-one attention through the peak becomes a logistics problem rather than a care decision.
7. Red flags to walk away from.
Toad branding. “Ancient shamanic 5-MeO-DMT” framing. No medical staff named on the site.
No screening process you can read before paying. All-cash, no paperwork. Any one of these, on its own, is enough to keep looking.
What we'd say to a friend
The Executive Order is good news. It’ll pull research forward and likely shorten the path to legal access in the US by years.
We’re rooting for it. But the people most likely to act on the news right now are also the people most likely to skip the vetting.
If you’re one of them, if you’ve been quietly carrying something for years and the headline made you sit up, please take the list above seriously. With us. With anyone.
The right retreat will reward the questions. The wrong one will be annoyed by them. That’s most of the work, right there.
Take the next step
If you’re considering 5-MeO-DMT specifically:
The first conversation is a discovery call. No commitment, no sales script. We’re as interested in whether this is the right fit for you as you are. Book a discovery call with Tandava.
If you’re a veteran or someone whose interest is in ibogaine:
Our partner organisation Bassé Ibogaine, founded by Laura Shapiro, runs an established ibogaine programme. They’re the right first call for ibogaine specifically.
You probably saw the news. The Executive Order. Psychedelics finally going mainstream. And maybe, quietly, you’ve been wondering if this is your moment.
We’ve been thinking about that too.
Here’s the honest version. The EO is real. The funding is real. But it won’t put 5-MeO-DMT within reach in the US next month, or next year. What it will do, almost immediately, is send a lot of people looking. Most will start by Googling “psychedelic retreat Mexico” without much idea what to look for.
That’s why we wrote this. Not as another news summary. You can find those everywhere. This is the kind of read we’d want a friend to have before they booked anything. A guide for telling the difference between a real retreat and a hashtag.
What the EO does (and doesn’t do)
So what did the President actually sign?
The short version: the Executive Order, signed April 18, 2026, fast-tracks FDA review of psychedelic compounds with Breakthrough Therapy status. It puts $50 million of federal funding behind ibogaine research through ARPA-H. It expands Right to Try access for people with serious mental illness, and tells the VA to lean further into clinical trials with veterans.
What it doesn’t do matters just as much. It doesn’t legalize anything. It doesn’t reschedule any compound. And it doesn’t mention 5-MeO-DMT by name. The EO is mostly an ibogaine and psilocybin story, driven by veteran advocacy.
But laws aren’t the only thing news moves. Attention is. Search interest in “psychedelic retreat” spikes after a story like this. Most of that interest lands in Mexico, where 5-MeO-DMT work already happens legally. Which is fine, if you know what you’re booking.
How the EO got onto the President’s desk
Worth understanding how the news got here. It tells you something about who’s been doing the actual work.
The catalyst was veterans. In 2024 and 2025, Stanford researchers tracked thirty Special Operations veterans with traumatic brain injury and PTSD who flew to Mexico for a single ibogaine session. A month later, PTSD symptoms were down 88%. A year later, 71% no longer met diagnostic criteria.
Then came the testimony. Former Navy SEAL Robert O’Neill, Green Beret Chris Thompson, and Medal of Honor recipient Dakota Meyer spoke at the Texas Capitol in April 2025 in support of state-funded ibogaine research. Texas signed Senate Bill 2308, a $50 million ibogaine clinical trial program, into law that summer.
At the federal level, HHS Secretary Robert F. Kennedy Jr. made psychedelic access a stated priority. And the catalysing moment, by Trump’s own account: a text from Joe Rogan about ibogaine, with the reply “Sounds great. Do you want FDA approval? Let’s do it.”
So the policy story is, almost entirely, a veterans-and-ibogaine story. Our partners at Bassé Ibogaine, and researchers like Dr. Deborha Mash, have spent years on this work. We’re not claiming a piece of it. But the door it’s opening is wider than ibogaine alone.
Why 5-MeO-DMT is a different vetting problem
If you’ve spent time researching plant medicines, here’s the trap: the lessons don’t fully transfer.
The first reason is pharmacology. The peak of a 5-MeO-DMT experience is roughly 20 minutes. There’s no slow ascent.
The intensity arrives in under a minute. Whoever’s holding the space either has the skill for that moment, or they don’t. There’s no margin to figure it out as it unfolds.
The second is lineage, and it’s the part most marketing gets wrong. 5-MeO-DMT was first synthesised in 1936. The Sonoran Desert toad story you may have read often conflates 5-MeO-DMT with bufotenine, a different compound.
There’s no documented tradition of intentional 5-MeO-DMT use in indigenous practice. So when a retreat sells “ancient shamanic 5-MeO-DMT,” the lineage isn’t real. The compound is post-1936, and its modern use is post-1990s.
The third is trauma. 5-MeO-DMT can surface PTSD material at the peak of the experience. The skill the moment demands is psychological: recognizing dissociation, knowing when to ground, knowing when to do nothing.
This isn’t a knock on plant-medicine traditions. It’s just a different job, asking for different training.
Plant-medicine practitioners and trauma-trained 5-MeO-DMT facilitators: what’s actually different
A shaman working with ayahuasca, peyote, or iboga is doing something legitimate. These traditions stretch back centuries.
The training is real, the lineage is real, and the framework (spirit, ceremony, healer relationship) is honoured by the people inside it.
5-MeO-DMT facilitation is a different thing entirely. Not lesser. Different.
The frame is different. A shaman moves inside a cosmology. A trauma-trained 5-MeO-DMT facilitator moves inside a model of nervous-system regulation, attachment, and somatic awareness.
Both frames are useful. Only one of them is the right map for what happens at the peak of a 20-minute 5-MeO-DMT session.
The screening is different. Plant-medicine intake is often informal, weighted toward intention and readiness. A 5-MeO-DMT intake, the version we run anyway, looks at psychiatric history, current medication (especially MAOIs and SSRIs), and cardiovascular markers.
The in-session response is different. If a guest enters dissociation, the response isn’t ceremonial. It’s stabilisation, titration, and co-regulation. The language of trauma work, not the language of spirit work.
The training pathway is different. The public benchmark for 5-MeO-DMT facilitator training is F.I.V.E.’s 9-month trauma-informed refinement program, which our co-founder Victoria Wueschner runs.
Apprenticeship inside a shamanic tradition is a real credential. For plant medicine. It doesn’t transfer here automatically, the same way trauma-trained facilitator credentials don’t transfer the other way.
Different lineages. Different toolkits. Same goal: someone arriving home in their body.
How to vet any 5-MeO-DMT retreat (including ours)
If you take one thing from this post, take this list. Use it on us. Use it on anyone.
1. Is the 5-MeO-DMT synthetic, and can they tell you why that matters?
Synthetic gives a known dose. Toad-derived contains bufotenine and other variable compounds, including ones that affect the heart.
We use synthetic exclusively. If a retreat won’t tell you which, that’s the answer.
2. Is there licensed medical staff on-site during ceremonies?
This isn’t optional with 5-MeO-DMT. Cardiovascular response can be intense, and we have a physician on-site for every ceremony.
If a retreat doesn’t name medical staff on its site, ask. If they can’t answer, walk.
3. What’s the intake screening?
Specifically: psychiatric history, current medications (MAOIs and SSRIs especially), and cardiovascular markers. If there’s no screening call before you put down a deposit, the answer is that there’s no screening.
4. What’s the facilitator’s training pathway?
A real answer names a programme. F.I.V.E.’s trauma-informed refinement training is the public benchmark for 5-MeO-DMT specifically. “I’ve done this hundreds of times” isn’t a training pathway.
5. What does the work after the ceremony look like, and for how long?
The ceremony is the start, not the deliverable. We run two weeks of preparation before and four weeks of integration support after. A retreat that ends when you fly home is a retreat that ends too early.
6. How many guests at a time?
Our cap is six. Above that, one-to-one attention through the peak becomes a logistics problem rather than a care decision.
7. Red flags to walk away from.
Toad branding. “Ancient shamanic 5-MeO-DMT” framing. No medical staff named on the site.
No screening process you can read before paying. All-cash, no paperwork. Any one of these, on its own, is enough to keep looking.
What we'd say to a friend
The Executive Order is good news. It’ll pull research forward and likely shorten the path to legal access in the US by years.
We’re rooting for it. But the people most likely to act on the news right now are also the people most likely to skip the vetting.
If you’re one of them, if you’ve been quietly carrying something for years and the headline made you sit up, please take the list above seriously. With us. With anyone.
The right retreat will reward the questions. The wrong one will be annoyed by them. That’s most of the work, right there.
Take the next step
If you’re considering 5-MeO-DMT specifically:
The first conversation is a discovery call. No commitment, no sales script. We’re as interested in whether this is the right fit for you as you are. Book a discovery call with Tandava.
If you’re a veteran or someone whose interest is in ibogaine:
Our partner organisation Bassé Ibogaine, founded by Laura Shapiro, runs an established ibogaine programme. They’re the right first call for ibogaine specifically.